Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment

Journal of Urology

Volumn 156, Issue 2, 1996, Pages 363-367

  Soloway, Mark S ^a   Briggman, Joseph V ^a   Carpinito, Gennaro A ^a   Chodak, Gerald W ^a   Church, Paul A ^a   Lamm, Donald L ^a   Lange, Paul ^a   Messing, Edward ^a   Pasciak, Robert M ^a   Reservitz, George B ^a   Rukstalis, Daniel B ^a   Sarosdy, Michael F ^a   Stadler, Walter M ^a   Thiel, Robert P ^a   Hayden, Cheryl L ^a  

^a NONE

Author keywords

Biological; Immunoassay; carcinoma; Transitional cell; bladder neoplasms; tumor markers

Indexed keywords

NUCLEAR MATRIX PROTEIN 22; NUCLEAR PROTEIN; TUMOR MARKER;

ANALYTICAL EQUIPMENT; ARTICLE; BLADDER TUMOR; CLINICAL TRIAL; CONFIDENCE INTERVAL; CYSTOSCOPY; FOLLOW UP; HUMAN; PREDICTION AND FORECASTING; REPRODUCIBILITY; ROC CURVE; SENSITIVITY AND SPECIFICITY; TIME; TRANSITIONAL CELL CARCINOMA; TUMOR RECURRENCE; URINE;

CARCINOMA, TRANSITIONAL CELL; CONFIDENCE INTERVALS; CYSTOSCOPY; FOLLOW-UP STUDIES; HUMANS; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0030213562     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65851-8     Document Type: Article

References (10)

1. Abel, P. D.: Prognostic indices in transitional cell carcinoma of the bladder. Brit. J. Urol., 62: 103, 1988.
2. Badalament, R. A., Hermansen, D. K., Kimmel, M., Gay, H., Herr, H. W., Fair, W. R., Whitmore, W. F., Jr. and Melamed, M. R.: The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer, 60: 1423, 1987.
3. Ooms, E. C., Anderson, W. A., Alons, C. L., Boon, M. E. and Veldhuizen, R. W.: Analysis of the performance of pathologists in the grading of bladder tumors. Hum. Path., 14: 140, 1983.
4. Wiener, H. G., Vooijs, G. P. and van't Hof-Grootenboer, B.: Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol., 37: 163, 1993.
5. Keesee, S. K., Meneghini, M. D., Szaro, R. P. and Wu, Y. J.: Nuclear matrix proteins in human colon cancer. Proc. Natl. Acad. Sci., 91: 1913, 1994.
6. Khanuja, P. S., Lehr, J. E., Soule, H. D., Gehani, S. K., Noto, A. C., Choudhury, S., Chen, R. and Pienta, K. J.: Nuclear matrix proteins in normal and breast cancer cells. Cancer Res., 53: 3394, 1993.
7. Bidwell, J. P., Fey, E. G., van Wijnen, A. J., Penman, S., Stein, J. L., Lian, J. B. and Stein, G. S.: Nuclear matrix proteins distinguish normal diploid osteoblasts from osteosarcoma cells. Cancer Res., 54: 28, 1994.
8. American Joint Committee on Cancer: Manual for Staging of Cancer, 3rd ed. Philadelphia: J. B. Lippincott Co., pp. 171-176, 1988.
9. Sokal, R. R. and Rohlf, F. J.: Biometry: The Principles and Practices of Statistics in Biological Research. New York: W. H. Freeman & Co., p. 821, 1995.
10. Golijanin, D., Sherman, Y., Shapiro, A. and Pode, D.: Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine. Urology, 46: 173, 1995.